Get started
Author

Jamie Frankish

Observed names: Frankish, Jamie Ian, J Frankish, J. Frankish
ORCID: 0000-0003-2200-4320
Observed ORCID: 0000-0003-2200-4320
OpenAlex ID: A5074927984
Integrative Imaging Reveals SARS-CoV-2 Induced Reshaping of Subcellular Morphologies
2020 · Mirko Cortese, Ji-Young Lee, et al. · Cell Host & Microbe · 326
PDF
SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-κB
2022 · Christopher J. Neufeldt, Berati Cerikan, et al. · Communications Biology · 279
PDF
HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon
2018 · Pascal Mutz, Philippe Metz, et al. · Gastroenterology · 152
PDF
TLR3 Activation by Zika Virus Stimulates Inflammatory Cytokine Production Which Dampens the Antiviral Response Induced by RIG-I-Like Receptors
2021 · Agnieszka Plociennikowska, Jamie Frankish, et al. · Journal of Virology · 50
Antiviral activity of bone morphogenetic proteins and activins
2018 · Lucy A. Eddowes, Kinda Al-Hourani, et al. · Nature Microbiology · 32
The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy
2023 · Jamie Frankish, Debayan Mukherjee, et al. · Frontiers in Immunology · 25
High-resolution kinetic characterization of the RIG-I-signaling pathway and the antiviral response
2023 · Sandy S Burkart, Darius Schweinoch, et al. · Life Science Alliance · 16
PDF
Increased functional potency of multi-edited CAR-T cells manufactured by a non-viral transfection system
2024 · Aine O’Sullivan, Sarah Case, et al. · Molecular Therapy — Methods & Clinical Development · 5
High-throughput screening of E3 ubiquitin ligases identifies TRIM48 as a novel negative regulator of RIG-I signaling
2025 · Guandi Wu, Jamie Frankish, et al. · Cellular Signalling · 2
HBV bypasses the innate immune system and does not protect HCV against the antiviral effect of IFN
2018 · P Mutz, P Metz, et al. · Zeitschrift für Gastroenterologie · 2
A scalable, rapid and automated manufacturing platform, Solupore®, a flexible offering for both autologous and allogeneic cell therapies.
2025 · L. Gallagher, D. Martin, et al. · Cytotherapy
Novel Non-viral Delivery Technology, Solupore®, Enables Gene Delivery for a Healthier, More Potent, and Significantly More Effective Car-t Therapy in Vivo.
2024 · J. Frankish · Cytotherapy
Gene Editing/Gene Therapies: SOLUPORE® IS A NOVEL PLATFORM USED FOR THE DELIVERY OF GENE EDITING TOOLS AND MODALITIES, YIELDING HEALTHIER, EDITED PRIMARY IMMUNE CELLS WITH SUPERIOR FUNCTION COMPARED WITH ELECTROPORATION
2023 · J. Frankish, A. O’Sullivan, et al. · Cytotherapy
Abstract 1587: Generation and characterization of novel bispecific molecules combining single-chain-CD40L with anti-CEA, anti-CD95L or anti-PD-L1 targeting moieties
2021 · Matthias Schroeder, Katharina Billian-Frey, et al. · Cancer Research
Works count: 15
Citation count: 889
H-index: 7
I10-index: 7
Year
Topic
Type